AstraZeneca Boosts Cancer Arsenal With 55% Acerta Pharma Stake

Mani

Published onDecember 17, 2015

Updated on May 13, 2021

AstraZeneca said Thursday it would buy 55% of privately held biotech firm Acerta Pharma for $4 billion to bolster the UK pharmaceutical giant’s blood cancer treatment portfolio.

The latest deal caps an intense period of deal making for the UK drug maker as it races to refill its drug portfolio.

AstraZeneca unveils strategic transaction with Acerta Pharma

The latest deal envisages AstraZeneca paying an upfront payment of $2.5 billion for the stake and then a further unconditional $1.5 billion upon receipt of the first U.S. regulatory approval for Acerta’s blood cancer drug, acalabrutinib, or the end...

Login required to continue reading.

Setup a free account to get access to this article (no credit card required).

View Full Article

Already a member? Log in here

Mani

Mani is a Senior Financial Consultant. He has worked in Senior Management role in large banking, financial and information technology organizations. He has provided solutions for major banking and securities firms across the globe in the area of retail, corporate and investment banking. He holds MBA (Finance) and Professional Management Accounting Qualifications. His hobbies are tracking global financial developments and watching sports

AstraZeneca Boosts Cancer Arsenal With 55% Acerta Pharma Stake

AstraZeneca unveils strategic transaction with Acerta Pharma

Login required to continue reading.

Get Your Business News